ChiCTR-INR-16009598
正在进行
/
/
/
2016-10-25
/
/
冠心病
基于智能手机的家庭心脏康复和冠心病患者二级预防的随机对照研究
基于智能手机的家庭心脏康复和冠心病患者二级预防的随机对照研究
The aim of the clinical trial is to assess the effects of smartphone-based cardiac rehabilitation and secondary prevention program on the short-term and long-term outcomes of post-PCI CHD patients, as well as its effects on improvement of quality of life, enhancing management of risk factors and medication, increasing cost benefits and reducing hospital readmissions.
随机平行对照
治疗新技术
The Project Manager will be supplied with one randomization envelope for each participant. It is the responsibility of the Project Manager to ensure that these randomization envelopes are safely stored, but readily available to the relevant staff. Once patients have signed the Consent Form, they will provided with a
/
Curtin University PhD research funding
/
300
/
2016-05-06
2019-05-05
/
Eligible participants will be patients diagnosed with coronary heart disease and received PCI. Inclusion criteria are that the participant must: Diagnosed by a clinician, have met criteria for diagnosis of CHD; Received PCI therapy during this admission; Aged between 18-70 years; Have an active smartphone, and have sufficient Chinese language proficiency to reading, speaking and listening; Able to operate smartphone for the purposes of trial; Living with at least one caregiver or guardian in the household; Presence of normal hemodynamics with a resting ejection fraction ≥ 50%; Able to individually consent; Not participating in any other clinical trial.；
请登录查看Unable to be involved in clinical follow up and treatment; Unable to operate smartphone for the purpose of the trial (eg, vision, hearing, cognitive or dexterity impairment); Had no experience with WeChat application; Have no internet connection at residence and smartphone Wi-Fi connection; Have contra-indication to CR.；
请登录查看Curtin University
/
Curtin University的其他临床试验
Curtin University的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
Curtin University相关推荐
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04